[go: up one dir, main page]

CA2692561A1 - Procede servant a produire de la solifenacine ou son sel - Google Patents

Procede servant a produire de la solifenacine ou son sel Download PDF

Info

Publication number
CA2692561A1
CA2692561A1 CA2692561A CA2692561A CA2692561A1 CA 2692561 A1 CA2692561 A1 CA 2692561A1 CA 2692561 A CA2692561 A CA 2692561A CA 2692561 A CA2692561 A CA 2692561A CA 2692561 A1 CA2692561 A1 CA 2692561A1
Authority
CA
Canada
Prior art keywords
solifenacin
formula
production method
phenyl
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2692561A
Other languages
English (en)
Other versions
CA2692561C (fr
Inventor
Masatoshi Inakoshi
Yusuke Ishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692561A1 publication Critical patent/CA2692561A1/fr
Application granted granted Critical
Publication of CA2692561C publication Critical patent/CA2692561C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2692561A 2004-04-28 2005-04-25 Procede servant a produire de la solifenacine ou son sel Expired - Fee Related CA2692561C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004133283 2004-04-28
JP2004-133283 2004-04-28
CA2564757A CA2564757C (fr) 2004-04-28 2005-04-25 Procede servant a produire de la solifenacine ou son sel

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2564757A Division CA2564757C (fr) 2004-04-28 2005-04-25 Procede servant a produire de la solifenacine ou son sel

Publications (2)

Publication Number Publication Date
CA2692561A1 true CA2692561A1 (fr) 2005-11-10
CA2692561C CA2692561C (fr) 2013-05-14

Family

ID=35241614

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2564757A Expired - Fee Related CA2564757C (fr) 2004-04-28 2005-04-25 Procede servant a produire de la solifenacine ou son sel
CA2692561A Expired - Fee Related CA2692561C (fr) 2004-04-28 2005-04-25 Procede servant a produire de la solifenacine ou son sel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2564757A Expired - Fee Related CA2564757C (fr) 2004-04-28 2005-04-25 Procede servant a produire de la solifenacine ou son sel

Country Status (6)

Country Link
US (1) US7829715B2 (fr)
EP (2) EP1757604B1 (fr)
JP (3) JPWO2005087231A1 (fr)
CA (2) CA2564757C (fr)
ES (2) ES2385892T3 (fr)
WO (1) WO2005105795A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560080A1 (fr) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Composition contenant de la solifenacine
CA2630846A1 (fr) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Procedes de preparation de solifenacine
US20080114028A1 (en) * 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
WO2008019057A2 (fr) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Polymorphes d'un intermédiaire de la solifénacine
WO2008120080A2 (fr) * 2007-03-30 2008-10-09 Medichem, S.A. Procédé amélioré de synthèse de solifénacine
US20100298371A1 (en) * 2007-12-04 2010-11-25 Mayank Ghanshyambhai Dave Process for preparing chemically and chirally pure solifenacin base and its salts
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
EP2406257B1 (fr) 2009-03-09 2019-08-07 Megafine Pharma (P) Ltd. Nouveau procédé de préparation de la solifénacine et nouvel intermédiaire dans sa préparation
WO2011048607A1 (fr) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Procédés de préparation de solifénacine ou d'un de ses sels
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
US8772491B2 (en) * 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
EP2867210A1 (fr) * 2012-07-02 2015-05-06 Pharmathen S.A. Procédé pour la préparation de solifénacine ou d'un de ses sels
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
CN103450183B (zh) * 2013-08-16 2017-09-12 威海迪素制药有限公司 一种琥珀酸索利那新的制备方法
CN104447734A (zh) * 2014-12-11 2015-03-25 荆楚理工学院 一种琥珀酸索利那新的合成方法
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
EP4255398B1 (fr) 2020-12-01 2024-08-07 Adamed Pharma S.A. Préparation administrée par voie orale contenant de la solifénacine et de la tamsulosine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
JP2002104968A (ja) 2000-09-28 2002-04-10 Senju Pharmaceut Co Ltd 毛様体筋の緊張緩和剤
ZA200309632B (en) 2001-07-10 2004-12-22 Yamanouchi Pharma Co Ltd Medicinal composition for treatment of interstitial cystitis.
JP2005509612A (ja) 2001-10-12 2005-04-14 アイアールエム エルエルシー 置換プリンの合成方法
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
CA2558877A1 (fr) * 2004-02-09 2005-08-18 Astellas Pharma Inc. Composition contenant du succinate de solifenacine
CA2670365A1 (fr) * 2006-11-22 2008-05-29 Medichem S.A. Procede perfectionne pour la synthese de solifenacine
PL385265A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej

Also Published As

Publication number Publication date
JPWO2005087231A1 (ja) 2008-01-24
JP2011084579A (ja) 2011-04-28
CA2564757A1 (fr) 2005-11-10
EP1757604A4 (fr) 2010-04-28
JPWO2005105795A1 (ja) 2008-03-13
EP2305676A1 (fr) 2011-04-06
CA2564757C (fr) 2011-08-02
EP2305676B1 (fr) 2012-10-17
US20070185329A1 (en) 2007-08-09
CA2692561C (fr) 2013-05-14
JP5278450B2 (ja) 2013-09-04
ES2393540T3 (es) 2012-12-26
ES2385892T3 (es) 2012-08-02
US7829715B2 (en) 2010-11-09
EP1757604B1 (fr) 2012-05-30
WO2005105795A1 (fr) 2005-11-10
EP1757604A1 (fr) 2007-02-28

Similar Documents

Publication Publication Date Title
JP5278450B2 (ja) ソリフェナシン又はその塩の製造法
JP2007231024A (ja) ３，３−ジアリルプロピルアミンの製造プロセス
JPWO2005075474A1 (ja) コハク酸ソリフェナシン含有組成物
NO327091B1 (no) Fremgangsmate for fremstilling av en enantiomerisk ren form eller en racemisk form av HMG-COA reduktaseinhibitorer
JP2018530582A (ja) 選択的ｎｒ２ｂアンタゴニスト
JP5234825B2 (ja) スルホンアミド化合物及びその結晶
AU2011254656A1 (en) Process for the preparation of chiral hydrazides
Del Bello et al. Novel muscarinic acetylcholine receptor hybrid ligands embedding quinuclidine and 1, 4-dioxane fragments
CA2560080A1 (fr) Composition contenant de la solifenacine
JP2009539901A (ja) キラルな新規中間体、その製造方法及びトルテロジン、フェソテロジン又はその活性代謝物の製造における新規中間体の使用
US7465751B2 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
CA2727669C (fr) Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
WO2009142521A1 (fr) Procédé de préparation de (s)-1-phényl-1,2,3,4-tetrahydroisoquinoléine enantiomériquement pure
JP4060523B2 (ja) カルボスチリル誘導体の製造法
US20030045547A1 (en) Process for producing carbostyril derivatives
JP2015521635A (ja) ソリフェナシン又はその塩の調製方法
WO2011086003A1 (fr) Procédé de préparation de solifénacine et de succinate de solifénacine
WO2006117754A1 (fr) Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
Sumiyoshi et al. Asymmetric synthesis of the 6-cyanoindole derivatives as non-steroidal glucocorticoid receptor modulators using (+)-and (−)-tert-butyl 6-cyano-3-[3-ethoxy-1, 1, 1-trifluoro-2-hydroxy-3-oxopropan-2-yl]-1H-indole-1-carboxylate
ZA200610054B (en) Benzymidazolone carboxylic acid derivatives
KR101069698B1 (ko) 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
JP2009018992A (ja) 光学活性ミルタザピンの製造方法
JPH107652A (ja) ピロリジン誘導体の製造方法
US20070191425A1 (en) Solifenacin-containing composition
WO2012078608A1 (fr) Préparation de phantasmidine et de ses analogues

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220425